|
|
|
| Clinical effect of Carapacis Trionycis Bolus treating hepatitis cirrhosis |
| LI Heng-fei1 YAN Deng-ying2 XU Jian1 CHEN Qin1 |
1.Department of Hepatology,Hubei Provincial Traditional Chinese Medical Hospital,Wuhan 430074,China;
2.Graduate School,Hubei University of Traditional Chinese Medicine,Wuhan 430061,China |
|
|
|
|
Abstract Objective To explore the clinical effect of Carapacis Trionycis Bolus treating hepatitis cirrhosis.Methods A total of 86 patients with hepatitis cirrhosis treated in Hubei Provincial Traditional Chinese Medical Hospital from February 2013 to February 2017 were selected as the study subjects,and they were divided into the the control group(n=43)and observation group(n=43)according to the order of medical treatment.The control group was treated by routine western medicine,mainly using Entecavir Dispersible Tablets,while the observation group was treated by combined method:Entecavir Dispersible Tablets+Carapacis Trionycis Bolus.HBV-DNA negative condition,liver function index and liver fibrosis before and after treatment were compared between the two groups.Results The negative rate of HBV-DNA was 44.19%in the 12thweek,and it was 58.14%in the 24th week and 93.02%in the 48thweek in the observation group,which was higher than that of the control group (25.58%,32.56%,48.84%)respectively,and the differences were statistically significant(P＜0.05).There was no significant difference in the levels of STB,ATL and ALB before treatment between the two groups(P＞0.05),after treatment,the levels of STB and ATL were lower than those before treatment,and the levels of ALB were higher than those before treatment in the two groups,and the differences were statistically significant(P＜0.05),after treatment,the levels of STB and ALB in the observation group were higher than those in the control group,and the level of ATL was lower than that in the control group (P＜0.05).There was no significant difference in the levels of CL-Ⅳ,PCⅢ,LN and HA before treatment between the two groups(P＞0.05).After treatment,the levels of CL-Ⅳ,PCⅢ,LN and HA in the two groups were significantly lower than those before treatment,and the differences were statistically significant(P＜0.05).The levels of CL-Ⅳ,PCIII,LN and HA in the observation group were lower than those in the control group after treatment,and the differences were statistically significant(P＜0.05).Conclusion Carapacis Trionycis Bolus treating hepatitis cirrhosis can inhibit HBV-DNA polymerase to a certain extent,reduce HBV replication,alleviate liver inflammation and fibrosis,reduce the incidence of canceration and complications,clinical effect is satisfactory,and it is worthy of further promotion and application.
|
|
|
|
|
|
| [1] |
Wang FY，Li B，Li Y，et al.Entecavir for patients with hepatitis B decompensated cirrhosis in China：a meta-analysis[J].Sci Rep，2016，6：32 722.
|
| [2] |
Huang R，Wang J，Zhao XA，et al.The impact of cirrhosis on the efficacy and safety of entecavir for patients with chronic hepatitis B[J].Eur J Gastroenterol Hepatol，2017，29（11）：1314.
|
| [3] |
徐礼通，杨平.鳖甲煎丸对慢性乙型肝炎早期肝硬化患者血清肿瘤坏死因子-α和白细胞介素-6的影响[J].中国中西医结合消化杂志，2014，22（1）：13-15.
|
| [4] |
张义红，井凤玲.鳖甲煎丸联合恩替卡韦治疗慢性乙型肝炎疗效观察[J].肝脏，2016，21（3）：197-200.
|
| [5] |
缪京翔.鳖甲煎丸抗乙肝后肝纤维化作用的机制研究[J].河南中医，2010，30（5）：457-459.
|
| [6] |
蒋华波，陆斌.鳖甲在抗肝纤维化和抗肝癌作用中的研究进展[J].基因组学与应用生物学，2017，36（4）：1446-1450.
|
| [7] |
任愉嫱，蒋燕.鳖甲煎丸治疗慢性乙型肝炎肝纤维化临床疗效的 Meta分析[J].现代中药研究与实践，2018，6（1）.112-113
|
| [8] |
徐玉玲，罗宏伟，丁沛.鳖甲煎丸对慢性乙型肝炎早期肝硬化患者肿瘤坏死因子-α和基质金属蛋白酶-2的影响[J].世界中医药，2017，12（9）：2077-2079.
|
| [9] |
黄晶晶，黄鸿娜，毛德文，等.鳖甲煎丸对二乙基亚硝胺诱导大鼠肝癌癌前病变的影响[J].辽宁中医杂志，2016，43（7）：1489-1491.
|
| [10] |
郑康，何盟国，王智翔，等.鳖甲煎丸和艾迪注射液联合肝动脉化疗栓塞治疗中晚期肝癌的疗效观察[J].安徽医药，2017，21（10）：1909-1912.
|
| [11] |
李烨，邓存良，彭颖.灵芪蠲肝胶囊对大鼠肝星状细胞增殖及TIMP-1表达的影响[J].中药新药与临床药理，2013，24（2）：155-159.
|
| [12] |
樊尔艳，贺松其，文彬，等.鳖甲煎丸对大鼠肝星状细胞增殖与凋亡的影响[J].中国中西医结合杂志，2016，36（8）：960-966.
|
| [13] |
主余华，张春清，石军，等.银杏叶提取物对大鼠肝星状细胞细胞因子和胶原合成及细胞增殖的影响[J].实用肝脏病杂志，2006，9（3）：129-132.
|
| [14] |
李云静.阿德福韦酯联合拉米夫定治疗乙肝肝硬化失代偿期的疗效及安全性评价[J].实用药物与临床，2012，15（12）：822-824.
|
|
|
|
